At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Exemestane +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Exemestane and Cyclophosphamide for Metastatic Beast Cancer. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Beast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedOct 2013
Primary CompletionOct 2017
TodayJul 2026
First PostedOct 16, 2013
Enrollment StartSep 1, 2013
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.7 years ago
Interventions
Exemestanedrug
Cyclophosphamidedrug